Amarin (AMRN) Dips Following FDA Orange Book Update
Tweet
Share
E-mailGet Alerts AMRN Hot Sheet
Join SI Premium – FREE
Amarin Corp Plc (NASDAQ: AMRN) shares are pressured following an update to the FDA's Orange Book.
The Book had Amarin's Vascepa with "no unexpired exclusivity for this product," though no NCE decision was made.
Shares are down 7.5 percent Friday afternoon.
The Book had Amarin's Vascepa with "no unexpired exclusivity for this product," though no NCE decision was made.
Shares are down 7.5 percent Friday afternoon.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Anthropic plans IPO potentially exceeding SpaceX's $86B record - Bloomberg
- Prime Video to invest $2 billion in Latin America by 2030
- Musalem: strong growth and investment influencing bond market - CNBC
Create E-mail Alert Related Categories
FDA, Momentum Movers, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
